{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:10:31Z","timestamp":1785881431487,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.arcmed.2024.103047","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T20:51:12Z","timestamp":1722286272000},"page":"103047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-9188","authenticated-orcid":false,"given":"Gustavo","family":"Martinez-Mier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro I.","family":"Moreno-Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-5101","authenticated-orcid":false,"given":"Luis F.","family":"Budar-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco T.","family":"M\u00e9ndez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Allende-Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Jim\u00e9nez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Barrera-Amoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Reyes-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.arcmed.2024.103047_bib0001","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0002","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1111\/ctr.12021","article-title":"The role of Thymoglobulin induction in kidney transplantation: an update","volume":"26","author":"Mourad","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0003","first-page":"CD00389","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","volume":"1","author":"Webster","year":"2010","journal-title":"Cochrane Database. Syst Rev"},{"key":"10.1016\/j.arcmed.2024.103047_bib0004","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus Basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2024.103047_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/TP.0b013e31825a7d1f","article-title":"On behalf of the Thymoglobulin Antibody Immunosuppression in Living Donor Recipient Investigators. Antithymocyte globulin induction in living donor renal transplant recipients: Final report of the TAILOR registry","volume":"94","author":"Gaber","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.arcmed.2024.103047_bib0006","doi-asserted-by":"crossref","first-page":"e12977","DOI":"10.1111\/ctr.12977","article-title":"The appropriate dose of Thymoglobulin induction therapy in kidney transplantation","volume":"31","author":"Nafar","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1432-2277.2006.00270.x","article-title":"Comparison of two dosages of Thymoglobulin used as a short-course for induction in kidney transplantation","volume":"19","author":"Wong","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.arcmed.2024.103047_bib0008","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1097\/TXD.0000000000000765","article-title":"Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation","volume":"4","author":"Singh","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.arcmed.2024.103047_bib0009","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.transproceed.2020.02.139","article-title":"Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience","volume":"52","author":"Jalalonmuhali","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.arcmed.2024.103047_bib0010","doi-asserted-by":"crossref","first-page":"10816","DOI":"10.3389\/ti.2023.10816","article-title":"Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients","volume":"36","author":"Masset","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.arcmed.2024.103047_bib0011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.transproceed.2011.01.035","article-title":"Low-dose rabbit antithymocyte globulin versus Basiliximab in low risk renal transplant recipients: 8 year follow-up","volume":"b43","author":"Laftavi","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.arcmed.2024.103047_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/1319-2442.124459","article-title":"Anti-thymocyte globulin versus Basiliximab induction in renal transplant recipients: Long-term outcome","volume":"25","author":"Kesiraju","year":"2014","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.arcmed.2024.103047_bib0013","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12659\/AOT.890069","article-title":"Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience","volume":"19","author":"Yang","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0014","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.transproceed.2020.01.054","article-title":"Low-dose Thymoglobulin vs. Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial","volume":"53","author":"Martinez-Mier","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.arcmed.2024.103047_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2024.103047_bib0017","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.transproceed.2008.08.082","article-title":"Induction Treatment With Low-Dose Thymoglobulin or Basiliximab in Renal Transplants From Older Donors","volume":"40","author":"Gavela Mart\u00ednez","year":"2008","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.arcmed.2024.103047_bib0018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.transproceed.2018.02.088","article-title":"Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience","volume":"50","author":"Lee","year":"2018","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.arcmed.2024.103047_bib0019","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.transproceed.2020.01.050","article-title":"Compliance With Biochemical Objectives in Patients on Renal Replacement Therapy Before Kidney Transplantation in Mexico","volume":"52","author":"Hern\u00e1ndez-Rivera","year":"2020","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.arcmed.2024.103047_bib0020","first-page":"507","article-title":"Renal transplant waiting list mortality in COVID era: is it advisable to halt transplant activity?","volume":"91","author":"Mart\u00ednez-Ulloa-Torres","year":"2023","journal-title":"Cir Cir"},{"key":"10.1016\/j.arcmed.2024.103047_bib0021","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1111\/ajt.16801","article-title":"Transplant trends in Mexico during the COVID-19 pandemic: Disparities within healthcare sectors","volume":"21","author":"Servin-Rojas","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.arcmed.2024.103047_bib0022","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.arcmed.2021.01.003","article-title":"Surgical Outcomes During COVID-19 Pandemic","volume":"52","author":"Nachon-Acosta","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2024.103047_bib0023","unstructured":"Portal de compras IMSS. http:\/\/compras.imss.gob.mx\/?P=imsscomprofich&f=16570396&pr=. (Accessed October 9, 2023)."},{"key":"10.1016\/j.arcmed.2024.103047_bib0024","unstructured":"Portal de compras IMSS. http:\/\/compras.imss.gob.mx\/?P=imsscomprofich&f=16567999&pr=. (Accessed October 9, 2023)."}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924000997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924000997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:27:13Z","timestamp":1726352833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440924000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0188440924000997"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103047","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103047"}}